Pharmacokinetic properties of LMW-heparin-tyramine fractions with high or low affinity to antithrombin III in the rat

Seminars in Thrombosis and Hemostasis

Volumn 23, Issue 1, 1997, Pages 31-37

  Stehle, Gerd ^a   Wunder, Andreas ^a   Sinn, Hannsjörg ^b   Schrenk, Hans H ^b   Harenberg, Job ^a   Malsch, Reinhard ^a   Maier Borst, Wolfgang ^a   Heene, Dieter L ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

pharmacokinetics, hepatic metabolism, low molecular weight heparin tyramine; pharmacology, heparins; Scavenger receptor, antithrombin III, heparins

Indexed keywords

ANTITHROMBIN III; LOW DENSITY LIPOPROTEIN; LOW MOLECULAR WEIGHT HEPARIN; TYRAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; BINDING SITE; CONFERENCE PAPER; CONTROLLED STUDY; DRUG ELIMINATION; FEMALE; LIVER METABOLISM; MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; RAT; RECEPTOR BLOCKING;

EID: 0030951997     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-996067     Document Type: Conference Paper

References (19)

1. Björk I, ST Olson, JD Shore: Molecular mechanisms of the accelerating effect of heparin on the reactions between antithrombin and clotting proteinases. In: Lane DA, U Lindahl (Eds): Heparin: Chemical and Biological Properties, Clinical Applications. Edward Arnold, London, 1989, pp 229-256.
2. Palm M, C Mattson: Pharmacokinetics of Fragmin. A comparative study in the rabbit of its high and low affinity forms for antithrombin.Thromb Res 48:51-62, 1987.
3. Boneu B, MR Buchanan, C Caranobe. AM Gabaig, D Dupouy, P Sie, J Hirsh: The disappearance of a low molecular weight heparin fraction (CY 216) differs from standard heparin in rabbits. Thromb Res 46:845-853, 1987.
4. Stehle G, EA Friedrich, H Sinn, A Wunder, J Harenberg, CE Dempfle, W Maier-Borst, DL Heene: Hepatic uptake of a modified low molecular weight heparin in the rat. J Clin Invest 90: 2110-2116, 1992.
5. Malsch R, M Guerrini, G Torri, G Löhr, B Casu, J Harenberg: Synthesis of a N'-alkylamine anticoagulant active low-molecular-mass heparin for radioactive and fluorescent labeling. Anal Biochem 217:255-264, 1994.
6. Stehle G, H Sinn, EA Friedrich, A Wunder, HH Schrenk, J Harenberg, P Peschke, CE Dempfle, W Maier-Borst, DL Heene: Altered pharmacokinetic properties of a lipophilically derivatized low molecular weight heparin in rats. J Lab Clin Med 122: 728-738, 1993.
7. Stehle G, A Wunder, H Sinn, HH Schrenk, EA Friedrich, CE Dempfle, W Maier-Borst, DL Heene: Complexes of a modified low molecular weight heparin with protamine are predominantly cleared by a macrophage scavenger receptor mediated process in rats. J Surg Res 58:197-204, 1995.
8. Wunder A, G Stehle, H Sinn, HH Schrenk, B Neufeld, CE Dempfle, HA Dresel, EA Friedrich, J Harenberg, W Maier-Borst, DL Heene: The injection of heparin prolongs plasma clearance of oxidized low density lipoprotein in the rat. Thromb Res 78:139-149, 1995.
9. Sinn H, HH Schrenk, EA Friedrich, DP Via, HA Dresel: Radioiodination of proteins and lipoproteins using N-bromosuccinimide as oxidizing agent. Anal Biochem 170:186-192, 1988.
10. Peterson TE, G Dudeck-Wojciechowska, L Sottrup-Jensen, S Magnussen: Primary structure of antithrombin III (heparin co-factor), partial homology between anti-trypsin and antithrombin III. In: Collen D, B Wiman, M Verstraete (Eds): The Physiologic Inhibitors of Blood Coagulation and Fibrinolysis. Elsevier, Amsterdam, 1979, pp 43-54.
11. Ottnad E, DP Via, H Sinn, E Friedrich, R Ziegler, HA Dresel: Binding characteristics of reduced hepatic receptors for acetylated low-density lipoprotein and maleylated bovine serum albumin. Biochem J 265:689-698, 1990.
12. Lee HB, MD Blaufox: Blood volume in the rat. J Nucl Med 26:72-76, 1985.
13. Harenberg J, C Giese, CE Dempfle, G Stehle, DL Heene: Monitoring of heparin and low molecular weight heparin with capillary and venous whole blood. Thromb Haemostas 60:377-381, 1988.
14. Caranobe C, M Petitou, D Dupouy, AM Gabaig, P Sie, MR Buchanan, B Boneu: Heparin fractions with high and low affinities to antithrombin III are cleared at different rates. Thromb Res 43:635-641, 1986.
15. Palm M, C Mattsson: Pharmacokinetics of heparin and low molecular weight heparin fragment (Fragmin) in rabbits with impaired renal or metabolic clearance. Thromb Haemostas 58: 932-935, 1987.
16. Barzu T, P Mohlo, G Tobelem, M Petitou, J Caen: Binding and endocytosis of heparin by human endothelial cells in culture. Biochim Biophys Acta 845:196-203, 1985.
17. Barzu T, P Molho, G Tobelem, M Petitou, JP Caen: Binding of heparin and low molecular weight heparin fragments to human vascular endothelial cells in culture. Nouv Rev Fr Hematol 26: 243-247, 1984.
18. Casu B, P Oreste, G Torri, G Zopetti, J Choay, JC Lormeau, M Petitou, P Sinay: The structure of heparin oligosaccharide fragments with higher-(factor Xa) activity containing the minimal antithrombin III binding sequence. Biochem J 197:599-609, 1981.
19. Petitou M: Synthetic heparin fragments: New and efficient tools for the study of heparin and its interactions. Nouv Rev Fr Hematol 26:221-226, 1984.